Radiation Oncology

Radiation therapy uses high-energy radiation to damage cancer cells' DNA and destroy their ability to divide and grow. It is delivered using linear accelerators, proton accelerators, metered cobalt-60 exposure, or brachytherapy where radioactive seeds are placed inside the patient on a temporary or permanent basis to kill cancer or relieve pain. The main radiation oncology society and annual conference is the American Society of Radiation Oncology (ASTRO).

healthcare money economics dollar stethoscope acquire merger

Siemens Healthineers to receive $60M in federal funding for key cancer therapy

Photon flash therapy is an experimental treatment that delivers an ultrahigh dose rate of radiotherapy 100 times faster than currently available options.

FDA clears Philips Rembra platform

FDA clears Philips' CT platform that streamlines and coordinates workflows

The product expands the capabilities of computed tomography within both diagnostic and radiation therapy settings, improving coordination between care teams. 

liver cancer

Interventional radiologist 1st in world to deliver newly approved cancer treatment

The completion of the first treatment represents a "significant milestone" for patients with liver cancer, the IR who led the procedure says.

Thumbnail

Treatment-related cancers on the rise, new study suggests

Therapy-related acute myeloid leukemia is an aggressive form of blood cancer and bone marrow that occurs in the years following radiation and chemotherapy. 

mergers and acquisitions handshake deal business

Radiopharma firm secures $85M to expand domestic production of radioisotopes

SpectronRx announced the funding on April 2, highlighting the critical need for a reliable domestic supply of radiopharmaceuticals.

Lantheus receives tentative FDA approval for its radio-equivalent to Lutathera

Lantheus’ version of a radiopharmaceutical capable of targeting somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been tentatively approved by the FDA.

Novartis

Novartis building massive new radioligand manufacturing facility as part of $23B investment in US

The 46,000 square foot Denton site will be the fifth Novartis has constructed stateside. The company expects it to be fully operational by 2028.

Radiopharmaceutical targeted toward treatment-resistant cancer put on FDA's Fast Track

The treatment addresses cancers that express Nectin-4, a protein found in excess of 80% to 90% of urothelial cancer patients.